Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Prestige Biologics Co Ltd banner
P

Prestige Biologics Co Ltd
KOSDAQ:334970

Watchlist Manager
Prestige Biologics Co Ltd
KOSDAQ:334970
Watchlist
Price: 2 855 KRW -2.89% Market Closed
Market Cap: ₩222B
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
+3%
5Y
+362%
10Y
-
Liabilities
+
3Y
+3%
5Y
+254%
10Y
-
Equity
+
3Y
+2%
5Y
+630%
10Y
-

Balance Sheet Decomposition
Prestige Biologics Co Ltd

Balance Sheet
Prestige Biologics Co Ltd

Rotate your device to view
Balance Sheet
Currency: KRW
Jun-2023 Jun-2024 Jun-2025
Assets
Cash & Cash Equivalents
45 435
29 507
1 582
Cash
45 435
29 507
1 582
Total Receivables
2 073
1 654
4 963
Accounts Receivables
1 432
599
438
Other Receivables
641
1 055
4 525
Inventory
6 833
17 805
26 909
Other Current Assets
15 901
6 669
7 395
Total Current Assets
70 242
55 636
40 848
PP&E Net
234 435
233 052
228 406
PP&E Gross
234 435
233 052
228 406
Accumulated Depreciation
21 096
32 075
44 931
Intangible Assets
1 047
677
1 032
Other Long-Term Assets
29
50
0
Total Assets
305 753
N/A
289 414
-5%
270 286
-7%
Liabilities
Accounts Payable
587
3 048
7 237
Accrued Liabilities
3 149
6 636
505
Short-Term Debt
0
0
0
Current Portion of Long-Term Debt
43 163
47 617
58 795
Other Current Liabilities
42 198
35 005
35 880
Total Current Liabilities
89 098
92 306
102 417
Long-Term Debt
116 853
125 426
32 666
Total Liabilities
205 950
N/A
217 732
+6%
135 083
-38%
Equity
Common Stock
30 554
30 751
38 876
Retained Earnings
189 063
218 437
245 907
Additional Paid In Capital
256 059
257 963
341 501
Other Equity
2 253
1 406
733
Total Equity
99 803
N/A
71 682
-28%
135 203
+89%
Total Liabilities & Equity
305 753
N/A
289 414
-5%
270 286
-7%
Shares Outstanding
Common Shares Outstanding
61
62
78

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 318,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.